455 related articles for article (PubMed ID: 24599824)
1. Assessment of [(18)F]-fluoroacetate PET/CT as a tumor-imaging modality: preclinical study in healthy volunteers and clinical evaluation in patients with liver tumor.
Takemoto K; Hatano E; Nishii R; Kagawa S; Kishibe Y; Takahashi M; Yamauchi H; Matsumura K; Zaima M; Toriguchi K; Tanabe K; Kitamura K; Seo S; Taura K; Endo K; Uemoto S; Higashi T
Ann Nucl Med; 2014 May; 28(4):371-80. PubMed ID: 24599824
[TBL] [Abstract][Full Text] [Related]
2. Early dynamic 18F-FDG PET to detect hyperperfusion in hepatocellular carcinoma liver lesions.
Schierz JH; Opfermann T; Steenbeck J; Lopatta E; Settmacher U; Stallmach A; Marlowe RJ; Freesmeyer M
J Nucl Med; 2013 Jun; 54(6):848-54. PubMed ID: 23528383
[TBL] [Abstract][Full Text] [Related]
3. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma.
Ho CL; Chen S; Yeung DW; Cheng TK
J Nucl Med; 2007 Jun; 48(6):902-9. PubMed ID: 17504862
[TBL] [Abstract][Full Text] [Related]
4. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses.
Ho CL; Yu SC; Yeung DW
J Nucl Med; 2003 Feb; 44(2):213-21. PubMed ID: 12571212
[TBL] [Abstract][Full Text] [Related]
5. F-18 FDG in conjunction with 11C-choline PET/CT in the diagnosis of hepatocellular carcinoma.
Wu HB; Wang QS; Li BY; Li HS; Zhou WL; Wang QY
Clin Nucl Med; 2011 Dec; 36(12):1092-7. PubMed ID: 22064078
[TBL] [Abstract][Full Text] [Related]
6. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
[TBL] [Abstract][Full Text] [Related]
7. Combined early dynamic (18)F-FDG PET/CT and conventional whole-body (18)F-FDG PET/CT provide one-stop imaging for detecting hepatocellular carcinoma.
Wang SB; Wu HB; Wang QS; Zhou WL; Tian Y; Li HS; Ji YH; Lv L
Clin Res Hepatol Gastroenterol; 2015 Jun; 39(3):324-30. PubMed ID: 25487755
[TBL] [Abstract][Full Text] [Related]
8. (4S)-4-(3-18F-fluoropropyl)-L-glutamate for imaging of xC transporter activity in hepatocellular carcinoma using PET: preclinical and exploratory clinical studies.
Baek S; Mueller A; Lim YS; Lee HC; Lee YJ; Gong G; Kim JS; Ryu JS; Oh SJ; Lee SJ; Bacher-Stier C; Fels L; Koglin N; Schatz CA; Dinkelborg LM; Moon DH
J Nucl Med; 2013 Jan; 54(1):117-23. PubMed ID: 23232273
[TBL] [Abstract][Full Text] [Related]
9. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.
Park JW; Kim JH; Kim SK; Kang KW; Park KW; Choi JI; Lee WJ; Kim CM; Nam BH
J Nucl Med; 2008 Dec; 49(12):1912-21. PubMed ID: 18997056
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of metabolic characteristics and viability of lipiodolized hepatocellular carcinomas using 18F-FDG PET/CT.
Kim HO; Kim JS; Shin YM; Ryu JS; Lee YS; Lee SG
J Nucl Med; 2010 Dec; 51(12):1849-56. PubMed ID: 21098794
[TBL] [Abstract][Full Text] [Related]
11. Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI.
Heusch P; Buchbender C; Beiderwellen K; Nensa F; Hartung-Knemeyer V; Lauenstein TC; Bockisch A; Forsting M; Antoch G; Heusner TA
Eur J Radiol; 2013 May; 82(5):870-6. PubMed ID: 23394765
[TBL] [Abstract][Full Text] [Related]
12. Role of ¹⁸F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma.
Pant V; Sen IB; Soin AS
Nucl Med Commun; 2013 Aug; 34(8):749-57. PubMed ID: 23689586
[TBL] [Abstract][Full Text] [Related]
13. Does dual-time-point
Wu B; Zhao Y; Zhang Y; Tan H; Shi H
Hell J Nucl Med; 2017; 20(1):79-82. PubMed ID: 28315913
[TBL] [Abstract][Full Text] [Related]
14. Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation.
Lin CY; Liao CW; Chu LY; Yen KY; Jeng LB; Hsu CN; Lin CL; Kao CH
Clin Nucl Med; 2017 Apr; 42(4):e183-e187. PubMed ID: 28114226
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
[TBL] [Abstract][Full Text] [Related]
16. Can positron emission tomography with the dual tracers [11 C]acetate and [18 F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma?
Cheung TT; Chan SC; Ho CL; Chok KS; Chan AC; Sharr WW; Ng KK; Poon RT; Lo CM; Fan ST
Liver Transpl; 2011 Oct; 17(10):1218-25. PubMed ID: 21688383
[TBL] [Abstract][Full Text] [Related]
17. (18)F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma.
Lee SD; Kim SH; Kim YK; Kim C; Kim SK; Han SS; Park SJ
Transpl Int; 2013 Jan; 26(1):50-60. PubMed ID: 23106431
[TBL] [Abstract][Full Text] [Related]
18. FDG PET/CT early dynamic blood flow and late standardized uptake value determination in hepatocellular carcinoma.
Bernstine H; Braun M; Yefremov N; Lamash Y; Carmi R; Stern D; Steinmetz A; Sosna J; Groshar D
Radiology; 2011 Aug; 260(2):503-10. PubMed ID: 21555347
[TBL] [Abstract][Full Text] [Related]
19. Value of ¹⁸F-FDG-PET/CT in the detection of recurrent hepatocellular carcinoma after hepatectomy or radiofrequency ablation: a comparative study with contrast-enhanced ultrasound.
Wang XY; Chen D; Zhang XS; Chen ZF; Hu AB
J Dig Dis; 2013 Aug; 14(8):433-8. PubMed ID: 23615075
[TBL] [Abstract][Full Text] [Related]
20. Quantitative assessment of simultaneous F-18 FDG PET/MRI in patients with various types of hepatic tumors: Correlation between glucose metabolism and apparent diffusion coefficient.
Kong E; Chun KA; Cho IH
PLoS One; 2017; 12(7):e0180184. PubMed ID: 28672016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]